Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F11%3A10737" target="_blank" >RIV/00216208:11110/11:10737 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/11:7082 RIV/00064203:_____/11:7082 RIV/00023736:_____/11:00009192 RIV/00064165:_____/11:10737

Výsledek na webu

<a href="http://dx.doi.org/10.3109/03630269.2011.578515" target="_blank" >http://dx.doi.org/10.3109/03630269.2011.578515</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome

Popis výsledku v původním jazyce

Forty-eight patients with early myelodysplastic syndrome (MDS) without excess of blasts, with average initial serum ferritin levels of 2739.5 microg/L (range 825-11287 microg/L), were treated with deferiprone (L1) in a daily dose of 40-90 mg/kg. Median duration of chelation treatment was 10.9 months (range 4-24 months). Chelation was effective (maintained or decreased iron stores) in 16 out of 22 patients (73%) with serum ferritin levels <2000 microg/L in contrast to only 12 out of 26 patients with serum ferritin levels >2000 microg/L. Combination of L1 with recombinant human erythropoietin (rHuEPO) (30-40 kU/week) resulted in effective chelation in five additional patients with serum ferritin levels >3000 microg/L. Incidence of adverse effects was comparable to that in thalassemic patients. Gastrointestinal symptoms represented the most frequent adverse effect of L1 therapy (37.5% of patients) that limited an effective escalation of the daily dose of the drug and led to discontinuatio

Název v anglickém jazyce

Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome

Popis výsledku anglicky

Forty-eight patients with early myelodysplastic syndrome (MDS) without excess of blasts, with average initial serum ferritin levels of 2739.5 microg/L (range 825-11287 microg/L), were treated with deferiprone (L1) in a daily dose of 40-90 mg/kg. Median duration of chelation treatment was 10.9 months (range 4-24 months). Chelation was effective (maintained or decreased iron stores) in 16 out of 22 patients (73%) with serum ferritin levels <2000 microg/L in contrast to only 12 out of 26 patients with serum ferritin levels >2000 microg/L. Combination of L1 with recombinant human erythropoietin (rHuEPO) (30-40 kU/week) resulted in effective chelation in five additional patients with serum ferritin levels >3000 microg/L. Incidence of adverse effects was comparable to that in thalassemic patients. Gastrointestinal symptoms represented the most frequent adverse effect of L1 therapy (37.5% of patients) that limited an effective escalation of the daily dose of the drug and led to discontinuatio

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Hemoglobin

ISSN

0363-0269

e-ISSN

—

Svazek periodika

35

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

217-227

Kód UT WoS článku

000290797500005

EID výsledku v databázi Scopus

—